SR One Capital Management, LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 13, 2025), SR One Capital Management, LP reported 12 stock positions worth $389.3 million. Its top holding was Arcellx (ACLX) at 39.5% of the portfolio, followed by Ars Pharmaceuticals (SPRY, 13.0%) and Mineralys Therapeutics (MLYS, 12.8%). Compared with Q4 2024, it opened 1 new position and added to 1. The biggest buy was Mineralys Therapeutics (MLYS, shares +55%).
- Most Recent 13F
- Q2 2026
- Location
- Redwood City, CA
- CIK
- 0001910264
- Portfolio Value
- $389.3M (Q1 2025)
- SEC Filing
- 0000950123-25-004926 ↗ filed May 13, 2025
Holdings Value
Holdings 12 stocks · $389.3M
| ACLX Arcellx Inc. | 39.54% | 2,346,630 | $153.9M | No change |
| SPRY Ars Pharmaceuticals Inc. | 12.97% | 4,012,903 | $50.5M | No change |
| MLYS Mineralys Therapeutics Inc. | 12.76% | 3,127,933 | $49.7M | Add +55.1% |
| ZBIO Zenas Biopharma Inc. | 9.97% | 4,911,539 | $38.8M | No change |
| CRSP Crispr Therapeutics AG | 9.17% | 1,048,951 | $35.7M | No change |
| DSGN Design Therapeutics Inc. | 6.47% | 6,526,476 | $25.2M | No change |
| ALMS Alumis Inc. | 3.09% | 1,959,896 | $12.0M | No change |
| OCS Oculis Holding AG | 1.58% | 322,500 | $6.1M | New |
| NKTX Nkarta Inc. | 1.58% | 3,333,333 | $6.1M | No change |
| ORKA Oruka Therapeutics Inc. | 1.13% | 430,330 | $4.4M | No change |
| KALA Kala Bio Inc. | 0.88% | 598,940 | $3.4M | No change |
| ENGN Engene Holdings Inc. | 0.86% | 747,750 | $3.3M | No change |
Portfolio Sells Q4 2024 → Q1 2025
| None this quarter. | |||
Portfolio Buys Q4 2024 → Q1 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $1.0B | MANE, ZBIO, CRSP, AVLN, DSGN |
| Q1 2026 | 14 | $915.4M | ACLX, MANE, ZBIO, CRSP, DSGN |
| Q4 2025 | 13 | $706.4M | ZBIO, ACLX, CRSP, DSGN, MLYS |
| Q3 2025 | 12 | $691.4M | ACLX, CRSP, ZBIO, MLYS, ORIC |
| Q2 2025 | 13 | $461.4M | ACLX, SPRY, CRSP, ZBIO, ORIC |
| Q1 2025 | 12 | $389.3M | ACLX, SPRY, MLYS, ZBIO, CRSP |
| Q4 2024 | 11 | $410.1M | ACLX, SPRY, CRSP, DSGN, ZBIO |
| Q3 2024 | 11 | $498.7M | ACLX, ZBIO, SPRY, CRSP, DSGN |
| Q2 2024 | 9 | $319.4M | ACLX, CRSP, SPRY, ALMS, MLYS |
| Q1 2024 | 6 | $364.1M | ACLX, CRSP, SPRY, NKTX, DSGN |